NASDAQ:SAGESAGE Therapeutics Stock Price, Forecast & News

$35.72

-1.66 (-4.44 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$35.35

Now: $35.72▼

$37.74

50-Day Range

$27.80

MA: $35.86▼

$40.87

52-Week Range

$25.01

Now: $35.72▼

$193.56

Volume1.14 million shs

Average Volume950,129 shs

Market Capitalization$1.85 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.75

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

4.3 Analyst's Opinion

Consensus Rating
SAGE Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.61, and is based on 11 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $82.11, SAGE Therapeutics has a potential upside of 129.9% from its current price of $35.72.
Amount of Analyst Coverage
SAGE Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.1 Community Rank

Outperform Votes
SAGE Therapeutics has received 574 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
SAGE Therapeutics has received 347 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
SAGE Therapeutics has received 62.32% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote “Outperform” if you believe SAGE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
SAGE Therapeutics does not currently pay a dividend.
Dividend Growth
SAGE Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SAGE Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.80% of the stock of SAGE Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for SAGE Therapeutics are expected to grow in the coming year, from ($9.99) to ($9.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SAGE Therapeutics is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SAGE Therapeutics is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SAGE Therapeutics has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SAGE

Previous Symbol

CUSIPN/A

CIK1597553

Webwww.sagerx.com

Phone617-299-8380

Debt

Debt-to-Equity Ratio0.03

Current Ratio12.77

Quick Ratio12.77

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.87 million

Price / Sales269.95

Cash FlowN/A

Price / Cash FlowN/A

Book Value$16.36 per share

Price / Book2.18

Profitability

EPS (Most Recent Fiscal Year)($13.38)

Net Income$-680,240,000.00

Net Margins-7,406.75%

Return on Equity-63.13%

Return on Assets-56.60%

Miscellaneous

Employees637

Outstanding Shares51,920,000

Market Cap$1.85 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

How has SAGE Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

SAGE Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SAGE stock has decreased by 15.6% and is now trading at $35.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SAGE Therapeutics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SAGE Therapeutics.

When is SAGE Therapeutics' next earnings date?

SAGE Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for SAGE Therapeutics.

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.44) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($3.17) by $0.73. The biopharmaceutical company earned $2.29 million during the quarter, compared to analysts' expectations of $2.81 million. SAGE Therapeutics had a negative return on equity of 63.13% and a negative net margin of 7,406.75%. The company's revenue was up 391.6% on a year-over-year basis. During the same period in the previous year, the company earned ($3.37) earnings per share. View SAGE Therapeutics' earnings history.

What price target have analysts set for SAGE?

18 Wall Street analysts have issued 12-month price targets for SAGE Therapeutics' stock. Their forecasts range from $28.00 to $263.00. On average, they expect SAGE Therapeutics' stock price to reach $82.11 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View analysts' price targets for SAGE Therapeutics.

Has SAGE Therapeutics been receiving favorable news coverage?

Media coverage about SAGE stock has been trending very negative on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. SAGE Therapeutics earned a coverage optimism score of -3.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutSAGE Therapeutics.

Who are some of SAGE Therapeutics' key competitors?

Some companies that are related to SAGE Therapeutics include Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY) and Zai Lab (ZLAB). View all competitors.

What other stocks do shareholders of SAGE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), salesforce.com (CRM) and Johnson & Johnson (JNJ).

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the following people:

Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
Mr. Michael Cloonan, Chief Bus. Officer (Age 48)

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are SAGE Therapeutics' major shareholders?

SAGE Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Capital International Investors (7.08%), BlackRock Inc. (5.29%), Invesco Ltd. (3.39%), State Street Corp (3.25%), JPMorgan Chase & Co. (2.71%) and Janus Henderson Group PLC (2.67%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View institutional ownership trends for SAGE Therapeutics.

Which institutional investors are selling SAGE Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Franklin Resources Inc., Frontier Capital Management Co. LLC, Bank of New York Mellon Corp, Pictet Asset Management Ltd., Invesco Ltd., Nuveen Asset Management LLC, and Capital International Investors. View insider buying and selling activity for SAGE Therapeutics.

Which institutional investors are buying SAGE Therapeutics stock?

SAGE stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Two Sigma Investments LP, Two Sigma Advisers LP, Victory Capital Management Inc., Victory Capital Management Inc., Voloridge Investment Management LLC, and Casdin Capital LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud, and Jeffrey M Jonas. View insider buying and selling activity for SAGE Therapeutics.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $35.72.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $1.85 billion and generates $6.87 million in revenue each year. The biopharmaceutical company earns $-680,240,000.00 in net income (profit) each year or ($13.38) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.

What is SAGE Therapeutics' official website?

The official website for SAGE Therapeutics is www.sagerx.com.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff